Cardiovascular and Renal Outcomes with Efpeglenatide in Type 2 Diabetes

This randomized, placebo controlled trial evaluated the cardiovascular and renal effects of efpeglenatide, a weekly GLP-1 receptor agonist, in 4,076 participants with type 2 diabetes and high cardiovascular risk. Over a median follow up of 1.81 years, efpeglenatide significantly reduced the risk of major adverse cardiovascular events (MACE) by 27% (hazard ratio, 0.73; 95% CI, 0.58–0.92) and composite renal outcomes by 32% (hazard ratio, 0.68; 95% CI, 0.57–0.79) compared to placebo. Gastrointestinal side effects were more common with efpeglenatide, but no significant safety concerns were observed. The findings suggest efpeglenatide offers cardiovascular and renal benefits for high risk patients with type 2 diabetes.

This randomized, placebo controlled trial evaluated the cardiovascular and renal effects of efpeglenatide, a weekly GLP-1 receptor agonist, in 4,076 participants with type 2 diabetes and high cardiovascular risk. Over a median follow up of 1.81 years, efpeglenatide significantly reduced the risk of major adverse cardiovascular events (MACE) by 27% (hazard ratio, 0.73; 95% CI, 0.58–0.92) and composite renal outcomes by 32% (hazard ratio, 0.68; 95% CI, 0.57–0.79) compared to placebo. Gastrointestinal side effects were more common with efpeglenatide, but no significant safety concerns were observed. The findings suggest efpeglenatide offers cardiovascular and renal benefits for high risk patients with type 2 diabetes.